1
|
Maisonneuve C, Tsang DKL, Foerster EG, Robert LM, Mukherjee T, Prescott D, Tattoli I, Lemire P, Winer DA, Winer S, Streutker CJ, Geddes K, Cadwell K, Ferrero RL, Martin A, Girardin SE, Philpott DJ. Nod1 promotes colorectal carcinogenesis by regulating the immunosuppressive functions of tumor-infiltrating myeloid cells. Cell Rep 2021; 34:108677. [PMID: 33503439 DOI: 10.1016/j.celrep.2020.108677] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Revised: 11/23/2020] [Accepted: 12/30/2020] [Indexed: 01/01/2023] Open
Abstract
Pioneering studies from the early 1980s suggested that bacterial peptidoglycan-derived muramyl peptides (MPs) could exert either stimulatory or immunosuppressive functions depending, in part, on chronicity of exposure. However, this Janus-faced property of MPs remains largely unexplored. Here, we demonstrate the immunosuppressive potential of Nod1, the bacterial sensor of diaminopimelic acid (DAP)-containing MPs. Using a model of self-limiting peritonitis, we show that systemic Nod1 activation promotes an autophagy-dependent reprogramming of macrophages toward an alternative phenotype. Moreover, Nod1 stimulation induces the expansion of myeloid-derived suppressor cells (MDSCs) and maintains their immunosuppressive potential via arginase-1 activity. Supporting the role of MDSCs and tumor-associated macrophages in cancer, we demonstrate that myeloid-intrinsic Nod1 expression sustains intra-tumoral arginase-1 levels to foster an immunosuppressive and tumor-permissive microenvironment during colorectal cancer (CRC) development. Our findings support the notion that bacterial products, via Nod1 detection, modulate the immunosuppressive activity of myeloid cells and fuel tumor progression in CRC.
Collapse
Affiliation(s)
- Charles Maisonneuve
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Derek K L Tsang
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | | | | | - Tapas Mukherjee
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Dave Prescott
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Ivan Tattoli
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Paul Lemire
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Daniel A Winer
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Pathology, Toronto General Hospital, University of Toronto, Toronto, ON M5S 1A8, Canada; Buck Institute for Research on Aging, Novato, CA 94945, USA
| | - Shawn Winer
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada; Saint Michael's Hospital, Toronto, ON M5B 1W8, Canada
| | - Catherine J Streutker
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada; Saint Michael's Hospital, Toronto, ON M5B 1W8, Canada
| | - Kaoru Geddes
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Ken Cadwell
- Kimmel Center for Biology and Medicine at the Skirball Institute, New York Grossman University Grossman School of Medicine, New York, NY 10016, USA; Department of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA; Division of Gastroenterology and Hepatology, Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA
| | - Richard L Ferrero
- Department of Molecular and Translational Sciences, Monash University, Clayton, 3800 VIC, Australia; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, 3168 VIC, Australia; Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, 3800 VIC, Australia
| | - Alberto Martin
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Stephen E Girardin
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Dana J Philpott
- Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada.
| |
Collapse
|
2
|
NOD2 modulates immune tolerance via the GM-CSF-dependent generation of CD103 + dendritic cells. Proc Natl Acad Sci U S A 2020; 117:10946-10957. [PMID: 32350141 DOI: 10.1073/pnas.1912866117] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Four decades ago, it was identified that muramyl dipeptide (MDP), a peptidoglycan-derived bacterial cell wall component, could display immunosuppressive functions in animals through mechanisms that remain unexplored. We sought to revisit these pioneering observations because mutations in NOD2, the gene encoding the host sensor of MDP, are associated with increased risk of developing the inflammatory bowel disease Crohn's disease, thus suggesting that the loss of the immunomodulatory functions of NOD2 could contribute to the development of inflammatory disease. Here, we demonstrate that intraperitoneal (i.p.) administration of MDP triggered regulatory T cells and the accumulation of a population of tolerogenic CD103+ dendritic cells (DCs) in the spleen. This was found to occur not through direct sensing of MDP by DCs themselves, but rather via the production of the cytokine GM-CSF, another factor with an established regulatory role in Crohn's disease pathogenesis. Moreover, we demonstrate that populations of CD103-expressing DCs in the gut lamina propria are enhanced by the activation of NOD2, indicating that MDP sensing plays a critical role in shaping the immune response to intestinal antigens by promoting a tolerogenic environment via manipulation of DC populations.
Collapse
|
4
|
Leclerc C, Deriaud E, Schutze MP, Chedid L. Prevention of low dose streptozotocin induced diabetes by muramyl dipeptide. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 1988; 10:293-8. [PMID: 2972632 DOI: 10.1016/0192-0561(88)90061-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The objective of the present investigation was to evaluate the effect of the synthetic immunomodulator MDP on an experimentally induced diabetes. It has been previously demonstrated that a single high dose of streptozotocin (STZ) induces hyperglycemia by direct destruction of pancreatic beta-cells. MDP had no effect on the diabetes induced by high dose STZ injection. However, MDP partially protected mice against the toxicity of STZ. In contrast to the first model, repeated low dosages of STZ have been shown to induce hyperglycemia due to autoimmune destruction of beta-cells. Large dosages of MDP given before these low dosages of STZ markedly decreased the diabetogenic effect of STZ. It is proposed that this protection is due to the immunosuppressive activity of MDP.
Collapse
Affiliation(s)
- C Leclerc
- Institut Pasteur, Department of Immunology, Paris, France
| | | | | | | |
Collapse
|